SLC8A1 and prostate carcinoma: In summary (Figure 7), we demonstrated that NCX1 is highly expressed in prostate cancer and that the reverse-mode NCX1 activity inhibitor KB-R7943 can inhibit cell cycle progression, migration, and proliferation both in vivo and in vitro.